It's not been the easiest year to raise funding, but Houston startup founders managed to secure over $160 million in VC or grant funding last quarter. Photo via Getty Images

The second quarter of 2023 looked a lot like the first when it came to venture capital funding for Houston companies. The whole country — affected by inflation, geopolitical instability, and other factors — has seen a trying time for investment opportunities.

Houston's performance is far from unique. Globally, VC funding is down — a reported 18 percent from Q1 to Q2, per Crunchbase. Year over year, that's a 49 percent decrease from 2022's Q2.

According to InnovationMap reporting, 10 Houston-based, Houston-founded, or soon-to-be Houston-headquartered companies announced VC or grant funding between April and June. Here's a roundup of these second quarter deals — click on each story to read more.


Houston-founded e-commerce unicorn Cart.com raises $60M series C 

Cart.com has secured its unicorn status at a $1.2B valuation with latest round of venture capital funding. Image via Cart.com

A Houston-founded software company — officially a unicorn company, valued at $1 billion or more — has announced the details of its latest fundraise.

Cart.com, which provides a suite of software solutions for commerce and logistics enablement, closed its $60 million series C equity funding round with a $1.2 billion valuation. Investors in the round included B. Riley Venture Capital, Kingfisher Investment Advisors, Snowflake Ventures, Prosperity7 Ventures, Legacy Knight, and more.

According to a news announcement from the company, Cart.com will use the funding for international expansion, continued product development, and to meet increased client demand. Continue reading.

Houston e-commerce company P97 Networks  raises another $40M round to support growth

P97 Networks has again raised $40 million to support its growth. Photo via Getty Images

For the second time in just over a year, a Houston business that provides mobile commerce and digital marketing to the mobility and fuel industries has raised $40 million.

P97 Networks, which has developed a cloud-based mobile commerce platform that helps brands securely do business with customers, announced that it has closed its series C round at $40 million. The equity financing round was led by Portage and included participation from existing investors. The fresh funding will go to support growth strategy.

"In this highly connected world, retail brands are looking for new ways to increase consumer engagement — the power of network effects in the digital world will be a key contributor to revenue growth and margins," says Donald Frieden, CEO of P97 Networks, in a news release. "With consumers of all ages further adopting mobile payment solutions, we are proud to have built the leading connected commerce and digital marketing platform for the convenience retail, energy marketing, and transportation industry." Continue reading.

Podcast: Houston home tech startup SmartAC.com raises $22M to grow sales

Josh Teekell, founder and CEO of SmartAC.com, joins the Houston Innovators Podcast to discuss the latest from his company, which just closed its series B. Photo courtesy

A Houston startup that combines unique sensor technology with software analysis has raised its next round of funding to — according to Founder and CEO Josh Teekell — turbocharge its sales.

SmartAC.com launched in 2020, emerging from stealth with $10 million raised in a series A. Over the past almost three years, the company has firmed up its hardware, developed its software, and pivoted slightly from selling directly to consumers to adopting a B2B approach.

Now, Teekell says he's focused on turbocharging sales to these contractors, and he's going to do that with the funding raised in the series B round that closed this month. He says the company will also grow its team that goes out to deploy the technology and train the contractors on the platform.

"This funding really buys us a couple years of runway through the end of next year and allows us to focus on getting to cash flow breakeven, which is right around our wheelhouse of our abilities here in the next 12 months," Teekell says. "In general, we've accomplished everything we'd be able to accomplish on the hardware side, and now it's just about deployment."

The $22 million SmartAC.com has raised came from local investors. Teekell, who hasn't announced the full list of the round's investors, explains that while traditionally startups might have more opportunity on the coasts for raising money, it's not hard to sell Houstonians on the benefits of SmartAC.com's optimized air conditioning. Continue reading.

Houston fintech startup Brassica raises $8M seed round led by Mercury

A Houston fintech startup is aiming to modernize banking and investing — and has received fresh funding to do it. Photo via Getty Images

A Houston startup has raised millions for its fintech platform — and the company didn't have to go very far to find its lead investor.

Brassica Technologies Inc. closed its seed round at $8 million with Houston-based Mercury Fund leading the round. Valor Equity Partners, Long Journey Ventures, NGC Fund, Neowiz, Broadhaven Ventures, Armyn Capital, VC3DAO, Alpha Asset Management (Korea), and other global FinTech investors participated in the round as well.

The startup's platform has "institutional-grade solutions for the new era of private investing and alternative assets," per the release. Serving the alternative assets industry, Brassica's tools can easily integrate with any operating system to provide proprietary technology and unique regulatory licenses. The technology aims to modernize key banking and investing infrastructure to help enterprises safely grow their business and protect their customer assets. Continue reading.

Houston immunotherapy company 7 Hills Pharma to use $13.5M CPRIT grant to further develop cancer treatments

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas. Continue reading.

Seattle biotech co. OncoResponse to move to Houston thanks to $13.3M grant from CPRIT

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release. Continue reading.

Houston biotech startup CellChorus secures $2.3M SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences. Continue reading.

Health tech startup Rosarium Health raises $1.7M, plans Houston HQ

Rosarium Health, a member of the Texas Medical Center's 2023 Accelerator for HealthTech cohort, has raised pre-seed funding. Photo courtesy of TMC

A health tech startup that just collected $1.7 million in pre-seed funding aims to eventually plant its headquarters in Houston.

The startup, Rosarium Health, currently has no headquarters; its 10 employees work remotely from various locations. However, co-founder and CEO Cameron Carter — who lives in the Denver area — says the company is eyeing a future headquarters in Houston.

“We believe Houston is the best city to launch a health care startup, given the Texas Medical Center, diverse talent across health and technology, affordable living, and a city with supportive and progressive communities,” Carter tells InnovationMap. “We feel Houston offers meaningful attributes that can enable a high-growth startup to succeed and for its employees to feel safe.” Continue reading.

Houston-based workforce solutions platform Innovapptive closes series B round

A Houston SaaS company has announced a fresh round of funding. Photo via Innovapptive.com

A Houston software-as-a-service company has closed an undisclosed amount of funding in a series B round.

Innovapptive Inc., which has its global headquarters in Greenway Plaza, has announced it's closed a series B investment round led by Austin-based Vista Equity Partners with support from existing investor Tiger Global Management. The fresh funding will be deployed to "accelerate product innovation and reach new regional markets," according to the company.

“We look forward to this next phase of growth as we continue to define the emerging connected worker software category,” says Sundeep Ravande, founder and CEO of Innovapptive, in the news release. “Vista has significant experience scaling enterprise software businesses and emerging technologies." Continue reading.

Venus Aerospace, a Houston startup with hypersonic engine tech, adds new investor

This Houston company is one step closer to enabling high-speed global travel. Photo courtesy of Venus Aerospace

A Houston-based company that's developing an engine that'll enable one-hour global transportation has announced its latest investor.

Venus Aerospace released the news that Silicon Valley venture capital firm, Airbus Ventures, has joined its team of investors. The supersonic combustion engine technology — more akin to a rocket's engine than an airplane's — is revolutionary because allows for travel at a higher elevation. Jet engines rely on air outside of the aircraft to combust, and rocket engines work with a system that supplies air internally.

“Venus has developed the world’s first liquid-propellant rotating detonation rocket engine (RDRE) with a double-digit percentage increase in efficiency over standard regular engines, making the hypersonic economy possible,” says Sassie Duggleby, CEO and co-founder of Venus, in a news release. “We’re delighted to bring Airbus Ventures into the Venus family and look forward to growing our collaboration as we harness the future of hypersonic flight.” Continue reading.

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Houston essentially matched Austin in venture capital funds received in the third quarter of 2018. Getty Images

Houston neck-and-neck with Austin in third quarter venture capital funding reports

It's on

It was a Texas showdown when it came to venture capital funding between Houston and Austin in the third quarter of 2018. According to Crunchbase data, Houston startups pulled in $138.8 million — 39.2 percent of the state's entire VC funding — while Austin startups reported receiving $150.6 million — 42.6 percent of the funds.

"It's something we've never even come close to before and, all of the sudden, boom, we're right there," Station Houston CEO Gabriella Rowe tells InnovationMap. "I think that's what we are going to continue to see in Houston."

"We're not going to see little wins now. We're going to start seeing big wins."

Before the startup scene can truly celebrate, it's worth noting that the entire state struggled in the third quarter. VCs contributed $353.7 million to Texas startups in 91 known deals, according to the report. That's less than half of what was reported in the second quarter, and, actually, it's less that what Austin alone received in Q2. However, the state is up year-over-year in VC funding by 11 percent, as the state only saw $319.6 million in Q3 of 2017.

Chart courtesy of Crunchbase

Crunchbase reported that the largest four funding rounds in Houston were as follows:

  • OncoResponse (immuno-oncology): $40 million in September
  • ViraCyte (biopharmaceuticals): $30 million in September
  • Enchanted Rock LLC (utilities): $23.6 million in July
  • DNAtriX (cancer treatment): $15.5 million in September
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas improves ranking on annual report of most innovative states

moving up

Texas ranks above average — but outside the top 10 — in a new index that ranks the most innovative states.

To come up with its Most and Least Innovative States ranking, personal finance website WalletHub looked at 25 key indicators of innovation for the 50 states and the District of Columbia. These include a state’s share of STEM professionals, research and development spending per capita, and the proliferation of tech companies.

With an innovation score of 48.96 out of 100, Texas lands at No. 13 on the list. The District of Columbia stands atop the list, with an innovation score of 69.79, followed by Massachusetts, California, Colorado, and Washington.

Texas has steadily inched up the list — the state was No. 14 on the list in 2024 and has climbed up one spot each year since 2021.

Two components make up each state’s score: human capital and “innovation environment.” Texas ranks 14th in the human capital category and 13th in the innovation environment category.

“The most innovative states are especially attractive to people who have majored in science, technology, engineering and math, or STEM, as they offer abundant career opportunities and investment dollars, both for jobs at existing companies and for startups,” says WalletHub analyst Chip Lupo. “These states also instill young students with the skills they need to succeed in the current workforce, skills which are useful whether or not they pursue a STEM career.”

Despite not placing in the top 10 of the WalletHub index, Texas continues to produce thousands of jobs.

Citing data from the U.S. Bureau of Labor Statistics, Gov. Greg Abbott says Texas added the most nonfarm jobs in January (27,900) of any state and the most nonfarm jobs from January 2024 to January 2025 (187,700).

“Texas is America’s jobs engine, adding more new jobs in the last year than any other state,” Abbot said in a news release. “Our skilled and growing workforce and our business-friendly climate attract job-creating businesses in diverse industries from across the country and around the world. … Texas continues to remove regulatory red tape and invest in education, innovation, and infrastructure as we build a stronger, more prosperous Texas than ever before.”

Houston researchers find AI provides fresh perspectives to everyday problems

houston voices

We all know ChatGPT has forever changed how we do business. It’s modified how we access information, compose content and analyze data. It’s revolutionized the future of work and education. And it has transformed the way we interact with technology.

Now, thanks to a recent paper by Jaeyeon (Jae) Chung (Rice Business), we also know it’s making us better problem solvers.

Key findings:

  • A recent study finds ChatGPT-generated ideas are deemed an average of 15% more creative than traditional methods.
  • ChatGPT enhances “incremental,” but not “radical,” innovation.
  • ChatGPT boosts creativity in tasks normally associated with human traits, like empathy-based challenges.

According to the study published in Nature Human Behavior by Chung and Byung Cheol Lee (University of Houston), ChatGPT enhances our problem-solving abilities, especially with everyday challenges. Whether coming up with gifts for your teenage niece or pondering what to do with an old tennis racquet, ChatGPT has a unique ability to generate creative ideas.

“Creative problem-solving often requires connecting different concepts in a cohesive way,” Chung says. “ChatGPT excels at this because it pulls from a vast range of data, enabling it to generate new combinations of ideas.”

Can ChatGPT Really Make Us More Creative?

Chung and Lee sought to answer a central question: Can ChatGPT help people think more creatively than traditional search engines? To answer this, they conducted five experiments.

Each experiment asked participants to generate ideas for solving challenges, such as how to repurpose household items. Depending on the experiment, participants were divided into one of two or three groups: one that used ChatGPT; one that used conventional web search tools (e.g., Google); and one that used no external tool at all. The resulting ideas were evaluated by both laypeople and business experts based on two critical aspects of creativity: originality and appropriateness (i.e., practicality).

In one standout experiment, participants were asked to come up with an idea for a dining table that doesn’t exist on the market. The ChatGPT group came up with suggestions like a “rotating table,” a “floating table” and even “a table that adjusts its height based on the dining experience.” According to both judges and experts, the ChatGPT group consistently delivered the most creative solutions.

On average, across all experiments, ideas generated with ChatGPT were rated 15% more creative than those produced by traditional methods. This was true even when tasks were specifically designed to require empathy or involved multiple constraints — tasks we typically assume humans might be better at performing.

However, Chung and Lee also found a caveat: While ChatGPT excels at generating ideas that are “incrementally” new — i.e., building on existing concepts — it struggles to produce “radically” new ideas that break from established patterns. “ChatGPT is an incredible tool for tweaking and improving existing ideas, but when it comes to disruptive innovation, humans still hold the upper hand,” Chung notes.

Charting the Next Steps in AI and Creativity

Chung and Lee’s paper opens the door to many exciting avenues for future study. For example, researchers could explore whether ChatGPT’s creative abilities extend to more complex, high-stakes problem-solving environments. Could AI be harnessed to develop groundbreaking solutions in fields like medicine, engineering or social policy? Understanding the nuances of the collaboration between humans and AI could shape the future of education, work and even (as many people fear) art.

For professionals in creative fields like product design or marketing, the study holds especially significant implications. The ability to rapidly generate fresh ideas can be a game-changer in industries where staying ahead of trends is vital. For now, take a second before you throw out that old tennis racquet. Ask ChatGPT for inspiration — you’ll be surprised at how many ideas it comes up with, and how quickly.

-----

This article originally appeared on Rice Business Wisdom. Based on research by Jaeyeon (Jae) Chung and Byung Cheol Lee (University of Houston). Lee and Chung, “An empirical investigation of the impact of ChatGPT on creativity.” Nature Human Behavior (2024): https://doi.org/10.1038/s41562-024-01953-1.


Rice, MD Anderson receive $1.5 million to further brain cancer research

fresh funding

Rice University chemist Han Xiao, who also serves as director of the university’s Synthesis X Center, and cancer biologist Dihua Yu of The University of Texas MD Anderson Cancer Center have received a three-year, $1.5 million grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation.

The funding will allow them to continue their research on treating brain metastasis by overcoming the blood-brain barrier, or the BBB, according to a news release.

Brain metastasis is the leading form of brain cancer, with survival rates below 20 percent within a year of diagnosis, according to the National Library of Medicine. It commonly originates from breast, lung and melanoma cancers.

The BBB typically acts as a protective barrier for the brain. However, it prevents most drugs from being able to directly reach the brain. According to Rice, only 2 percent of FDA-approved small molecule drugs can penetrate the BBB, limiting treatment options.

Xiao and Yu’s approach to dealing with the BBB includes a light-induced brain delivery (LIBD) platform. The advanced system employs nanoparticles that are embedded with a near-infrared dye for the transport of therapeutic agents across the BBB. The research will evaluate the LIBD’s ability to improve the delivery of small-molecule drugs and biological therapies. Some therapies have shown potential for reducing cancer growth in laboratory studies, but they have struggled due to limited BBB penetration in animal models.

“Our LIBD platform represents a novel strategy for delivering drugs to the brain with precision and efficiency,” Xiao said in a news release. “This technology could not only improve outcomes for brain metastasis patients but also pave the way for treating other neurological diseases.”

The Kleberg Foundation looks for groundbreaking medical research proposals from leading institutions that focus on “innovative basic and applied biological research that advances scientific knowledge and human health” according to the foundation.

“This research is a testament to the power of collaboration and innovation,” Xiao said in a news release. “Together, we’re pushing the boundaries of what’s possible in treating brain metastasis and beyond.”

Rice launched the Synthesis X Center, or Synth X, last spring. It was born out of what started about eight years ago as informal meetings between Xiao's research group and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center. It aims to turn fundamental research into clinical applications through collaboration.

“This collaboration builds on the strengths of both research teams,” Xiao said in the release. “By combining SynthX Center's expertise in chemistry with Dr. Yu's expertise in cancer biology and brain metastases, we aim to create a transformative solution.”